DK2474321T3 - Sammensætninger til behandling af collagenmedierede sygdomme - Google Patents

Sammensætninger til behandling af collagenmedierede sygdomme Download PDF

Info

Publication number
DK2474321T3
DK2474321T3 DK12155233.5T DK12155233T DK2474321T3 DK 2474321 T3 DK2474321 T3 DK 2474321T3 DK 12155233 T DK12155233 T DK 12155233T DK 2474321 T3 DK2474321 T3 DK 2474321T3
Authority
DK
Denmark
Prior art keywords
collagen
compositions
treatment
mediated diseases
mediated
Prior art date
Application number
DK12155233.5T
Other languages
Danish (da)
English (en)
Inventor
Gregory L Sabatino
Philip J Bassett
Hazel A Tharia
Antony G Hitchcock
Tito Jr Benjamin J Del
Original Assignee
Endo Global Ventures
Biospecifics Tech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endo Global Ventures, Biospecifics Tech Corp filed Critical Endo Global Ventures
Application granted granted Critical
Publication of DK2474321T3 publication Critical patent/DK2474321T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24007—Interstitial collagenase (3.4.24.7), i.e. matrix metalloprotease 1 or MMP1

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK12155233.5T 2006-01-30 2007-01-30 Sammensætninger til behandling af collagenmedierede sygdomme DK2474321T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US76347006P 2006-01-30 2006-01-30
US78413506P 2006-03-20 2006-03-20
US11/699,302 US7811560B2 (en) 2006-01-30 2007-01-29 Compositions and methods for treating collagen-mediated diseases
EP07762860.0A EP1987141B8 (en) 2006-01-30 2007-01-30 Compositions suitable for treating collagen-mediated diseases

Publications (1)

Publication Number Publication Date
DK2474321T3 true DK2474321T3 (da) 2019-06-03

Family

ID=38328033

Family Applications (2)

Application Number Title Priority Date Filing Date
DK12155233.5T DK2474321T3 (da) 2006-01-30 2007-01-30 Sammensætninger til behandling af collagenmedierede sygdomme
DK07762860.0T DK1987141T3 (en) 2006-01-30 2007-01-30 COMPOSITIONS SUITABLE FOR TREATING COLLAGEN-CONDUCTED DISEASES

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK07762860.0T DK1987141T3 (en) 2006-01-30 2007-01-30 COMPOSITIONS SUITABLE FOR TREATING COLLAGEN-CONDUCTED DISEASES

Country Status (17)

Country Link
US (16) US7811560B2 (enExample)
EP (6) EP2474321B1 (enExample)
JP (8) JP5309289B2 (enExample)
KR (2) KR20110046537A (enExample)
CN (2) CN101400788B (enExample)
AU (2) AU2007211313C1 (enExample)
BR (1) BRPI0708017A2 (enExample)
CA (1) CA2637262C (enExample)
DK (2) DK2474321T3 (enExample)
ES (3) ES2729941T3 (enExample)
HU (2) HUE044220T2 (enExample)
IL (6) IL291175B2 (enExample)
MX (1) MX2008009756A (enExample)
NZ (2) NZ569882A (enExample)
PT (2) PT1987141T (enExample)
TR (1) TR201903008T4 (enExample)
WO (1) WO2007089851A2 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6958150B2 (en) 1994-12-15 2005-10-25 Advance Biofactures Of Curacao, N.V. Reduction of adipose tissue
US20070224184A1 (en) * 2006-02-22 2007-09-27 The Research Foundation Of The State University Of New York Method for treating cellulite
US7811560B2 (en) * 2006-01-30 2010-10-12 Auxilium Us Holdings, Llc Compositions and methods for treating collagen-mediated diseases
US10071143B1 (en) 2007-05-03 2018-09-11 The Research Foundation For The State University Of New York Methods for non-surgical treatment of carpal tunnel syndrome
EP2725035A1 (en) 2007-10-02 2014-04-30 Avaxia Biologics, Inc. Antibody therapy for use in the digestive tract
US20100159564A1 (en) * 2007-11-30 2010-06-24 Dwulet Francis E Protease resistant recombinant bacterial collagenases
TWI395593B (zh) 2008-03-06 2013-05-11 Halozyme Inc 可活化的基質降解酵素之活體內暫時性控制
EP2130551B1 (en) 2008-06-02 2012-06-06 Roche Diagnostics GmbH Improved purification of collagenases from clostridium histolyticum liquid culture
US8236356B2 (en) 2008-06-11 2012-08-07 Roche Diagnostics Operations, Inc. Growth medium for Clostridium histolyticum
WO2010102262A1 (en) 2009-03-06 2010-09-10 Halozyme, Inc. Temperature sensitive mutants of matrix metalloprotease 1 und uses thereof
ES2385239B1 (es) 2010-09-30 2013-06-19 Proteos Biotech S.L.U. Uso de colagenasa g recombinante, colagenasa h recombinante y pz-peptidasa recombinante para el tratamiento de enfermedades que cursan con alteraciones del colágeno.
WO2012125948A1 (en) 2011-03-16 2012-09-20 Biospecifics Technologies Corp. Compositions and methods for producing clostridial collagenases
MX350145B (es) 2011-07-20 2017-08-28 Mediwound Ltd Extracto proteolitico a partir de bromelaina para el tratamiento de trastornos del tejido conectivo.
WO2013059619A1 (en) * 2011-10-21 2013-04-25 Auxilium Pharmaceuticals, Inc. Method of treating or reducing efp
EP4015627B1 (en) 2012-01-12 2023-09-27 Endo Global Ventures Clostridium histolyticum enzyme
ITPD20120118A1 (it) 2012-04-18 2013-10-19 Fidia Farmaceutici "nuovo processo di produzione e purificazione dell'enzima collagenasi da vibrio alginolyticus"
JP2015521169A (ja) 2012-05-01 2015-07-27 プロテオリース リミテッド 抜歯する方法
BR102012013110A2 (pt) 2012-05-31 2014-05-27 Cristalia Prod Quimicos Farm Meio de cultura para bactérias do gênero clostridium livre de componentes de origem animal e processo para produção de sobrenadante contendo uma ou mais proteases com atividade colagenolítica e gelatinolítica
US9636385B2 (en) 2012-10-24 2017-05-02 The Research Foundation For The State University Of New York Use of collagenase to treat glaucoma
US20150196625A9 (en) 2013-01-07 2015-07-16 Rudolph D. Paladini Metal Sensitive Mutants of Matrix Metalloproteases and uses thereof
EP3834840B8 (en) 2013-03-15 2025-09-17 Endo Biologics Limited Treatment method and product for uterine fibroids using purified collagenase
US20160000890A1 (en) * 2013-03-15 2016-01-07 Biospecifics Technologies Corp. Thermosensitive hydrogel collagenase formulations
CA2915814A1 (en) * 2013-06-18 2014-12-24 Imprimis Pharmaceuticals Inc. Local use of pentoxifylline to treat peyronie's disease
US10383875B2 (en) 2013-06-18 2019-08-20 Harrow Ip, Llc Pharmaceutical formulations of xanthine or xanthine derivatives, and their use
US10117892B2 (en) * 2013-08-29 2018-11-06 Allergan, Inc. Devices and methods for reducing the appearance of cellulite
CN103751102A (zh) 2014-01-15 2014-04-30 上海交通大学 一种胶原酶温敏水凝胶及其制备方法和应用
CN105477627B (zh) * 2014-09-19 2021-04-30 山东蓝金生物工程有限公司 治疗前列腺癌的组合物及其用途
CN105412917B (zh) * 2014-09-19 2021-04-30 达森生物药业有限公司 治疗实体瘤的抗癌组合物及其用途
CN105412916B (zh) * 2014-09-19 2021-04-30 达森生物药业有限公司 治疗乳腺癌的组合物及其用途
CN105477628B (zh) * 2014-09-19 2021-04-30 山东蓝金生物工程有限公司 抗癌组合物及其用途
DE202014105440U1 (de) * 2014-11-12 2016-02-15 Bilz Werkzeugfabrik Gmbh & Co. Kg Werkzeugaufnahme
KR101723168B1 (ko) 2015-04-28 2017-04-05 주식회사 대웅 보툴리눔 독소의 제조를 위한 배지 조성물
US10303245B2 (en) * 2015-05-04 2019-05-28 Adobe Inc. Methods and devices for detecting and responding to changes in eye conditions during presentation of video on electronic devices
KR20230003601A (ko) 2017-03-01 2023-01-06 엔도 벤쳐즈 리미티드 셀룰라이트를 평가하고 치료하기 위한 장치 및 방법
KR20240001279A (ko) 2017-03-28 2024-01-03 엔도 벤쳐즈 리미티드 개선된 콜라게나제 생성 방법
WO2020021332A2 (en) 2018-07-12 2020-01-30 Endo Global Aesthetics Limited Injection techniques for the treatment of cellulite
WO2020021330A2 (en) 2018-07-12 2020-01-30 Endo Global Aesthetics Limited Injection techniques for the treatment of cellulite
JP7628492B2 (ja) 2018-09-18 2025-02-10 エンド グローバル エステティックス リミテッド セルライトを治療するための組成物および方法
MX2021008017A (es) 2019-01-06 2021-08-05 Endo Global Aesthetics Ltd Formulaciones de colagenasa y metodos de produccion de las mismas.
CA3157517A1 (en) 2019-10-15 2021-04-22 The Johns Hopkins University Treatment of uterine fibroids using purified collagenase
WO2023131588A1 (en) 2022-01-05 2023-07-13 Nordmark Pharma Gmbh Culture medium for cultivating hathewaya histolytica (or clostridium histolyticum) and the production of one or more proteases
CN116102638B (zh) * 2023-01-09 2025-05-16 中国农业科学院农产品加工研究所 基于亲和吸附富集骨胶原蛋白成骨活性肽的方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61289885A (ja) * 1985-06-14 1986-12-19 Nitta Zerachin Kk コラゲナ−ゼおよびコラゲナ−ゼの製造方法
JP2898022B2 (ja) * 1989-09-05 1999-05-31 株式会社ニッピ コラーゲン分解酵素の製造方法
CA2047306A1 (en) * 1990-07-23 1992-01-24 Milan Holjevac Mutant bacterium clostridium histolyticum, a process for the obtaining thereof, and its use in the production of clostripain-free collagenase
US5393792A (en) * 1991-11-20 1995-02-28 Advance Biofactures Of Curacao, N.V. High dosage topical forms of collagenase
US5462739A (en) * 1991-11-21 1995-10-31 Yeda Research And Development Co., Ltd. Microdelivery device and method for enhanced drug administration to the eye
CA2138948A1 (en) * 1992-06-22 1994-01-06 Hun-Chi Lin Molecular cloning of the genes responsible for collagenase production from clostridium histolyticum
JP3186881B2 (ja) * 1993-02-18 2001-07-11 倉敷紡績株式会社 肝細胞の分離方法
US5332503A (en) * 1993-04-16 1994-07-26 Baxter International Inc. Process for purifying collagenase
CA2189646C (en) * 1994-06-24 1999-05-25 Francis E. Dwulet A purified mixture of collagenases and two other proteases obtained from clostridium histolyticum
US5589171A (en) 1994-08-22 1996-12-31 Advance Biofactures Of Curacao Treatment of Dupuytren's disease with collagenase
CZ280397A3 (cs) * 1995-03-16 1998-04-15 Knoll Aktiengesellschaft Nové, definované směsi enzymů pro získávání buněk a pro léčbu poranění
US5989888A (en) * 1996-01-24 1999-11-23 Roche Diagnostics Corporation Purified mixture of collagenase I, collagenase II and two other proteases
ATE272109T1 (de) * 1996-11-19 2004-08-15 Roche Diagnostics Gmbh Rekombinante collagenase typ i aus clostridium histolyticum und ihre verwendung zur isolierung von zellen und zellverbänden
US5830741A (en) * 1996-12-06 1998-11-03 Boehringer Mannheim Corporation Composition for tissue dissociation containing collagenase I and II from clostridium histolyticum and a neutral protease
US6086872A (en) 1997-03-27 2000-07-11 Advance Biofactures Of Curacao, Nv Amelioration of dupuytren's disease
JPH10262658A (ja) * 1997-03-28 1998-10-06 Kikkoman Corp ザルコシン・オキシダーゼの結晶、その製造方法及び三次元構造
US6022539A (en) 1999-06-03 2000-02-08 Advance Biofactures Of Curacao Amelioration of peyronie's disease
CN1308442C (zh) * 2001-07-02 2007-04-04 诺尔玛克药物有限责任及股份两合公司 纯化酶的方法和按此产生出的经纯化的酶以及该酶的用途
EP1462519A1 (en) * 2003-03-24 2004-09-29 Boehringer Ingelheim Austria GmbH Method and devices for producing biomolecules
JP4205496B2 (ja) * 2003-06-19 2009-01-07 三菱化学株式会社 新規カルボニル還元酵素及びこれをコードするｄｎａ、ならびにこれらを利用した光学活性アルコールの製造方法
NZ548871A (en) * 2004-01-30 2009-06-26 Shire Pharmaceuticals Ireland Use of arylsulfatase A for treating metachromatic leukodystrophy
US7355027B2 (en) * 2004-06-16 2008-04-08 Dynport Vaccine Company Llc Bacillus anthracis protective antigen
EP1781697B1 (en) * 2004-07-07 2009-04-22 H.Lundbeck A/S Novel carbamylated epo and method for its production
JP2008505928A (ja) * 2004-07-08 2008-02-28 アムジェン　インコーポレーテッド 治療用ペプチド
ES2548516T3 (es) * 2005-01-21 2015-10-19 The Research Foundation Of The State University Of New York Métodos para el tratamiento de la capsulitis adhesiva
US7811560B2 (en) * 2006-01-30 2010-10-12 Auxilium Us Holdings, Llc Compositions and methods for treating collagen-mediated diseases

Also Published As

Publication number Publication date
KR20110046537A (ko) 2011-05-04
ES2992881T3 (en) 2024-12-19
AU2012200863A1 (en) 2012-03-08
JP2009525283A (ja) 2009-07-09
EP4483952A2 (en) 2025-01-01
JP2021113212A (ja) 2021-08-05
US20100330065A1 (en) 2010-12-30
EP2474321A1 (en) 2012-07-11
US7811560B2 (en) 2010-10-12
WO2007089851A2 (en) 2007-08-09
AU2007211313A1 (en) 2007-08-09
AU2007211313B2 (en) 2011-12-01
IL277322A (en) 2020-10-29
AU2007211313C1 (en) 2014-05-22
IL264361A (en) 2019-02-28
CN105999244B (zh) 2022-01-11
EP2474319A1 (en) 2012-07-11
IL291175A (en) 2022-05-01
JP2017006143A (ja) 2017-01-12
ES2709202T3 (es) 2019-04-15
IL264361B (en) 2020-09-30
JP6792596B2 (ja) 2020-11-25
US20210106659A1 (en) 2021-04-15
IL254184B (en) 2019-02-28
JP2015128447A (ja) 2015-07-16
CA2637262C (en) 2014-08-19
EP2474321B1 (en) 2019-04-17
IL291175B1 (en) 2023-10-01
HUE041764T2 (hu) 2019-05-28
EP3508571A1 (en) 2019-07-10
NZ593907A (en) 2013-02-22
MX2008009756A (es) 2008-12-18
US20160000889A1 (en) 2016-01-07
US20110243909A1 (en) 2011-10-06
US20110243919A1 (en) 2011-10-06
US20110243908A1 (en) 2011-10-06
CN101400788B (zh) 2016-06-29
ES2729941T3 (es) 2019-11-07
US20100233151A1 (en) 2010-09-16
KR20080093142A (ko) 2008-10-20
TR201903008T4 (tr) 2019-03-21
JP5309289B2 (ja) 2013-10-09
EP2474320A1 (en) 2012-07-11
NZ569882A (en) 2012-03-30
US20110189153A1 (en) 2011-08-04
HUE044220T2 (hu) 2019-10-28
IL277322B (en) 2022-04-01
US20140004094A1 (en) 2014-01-02
EP1987141A4 (en) 2009-11-18
PT2474321T (pt) 2019-07-25
IL245434A (en) 2017-10-31
JP7191152B2 (ja) 2022-12-16
JP6389493B2 (ja) 2018-09-12
BRPI0708017A2 (pt) 2011-05-17
EP3508571B1 (en) 2024-08-21
JP6851943B2 (ja) 2021-03-31
WO2007089851A3 (en) 2008-01-03
JP2018143258A (ja) 2018-09-20
JP2020039371A (ja) 2020-03-19
PT1987141T (pt) 2019-03-04
JP2017218452A (ja) 2017-12-14
EP1987141B8 (en) 2019-03-06
IL192878A (en) 2013-03-24
EP1987141B1 (en) 2018-12-05
CN101400788A (zh) 2009-04-01
DK1987141T3 (en) 2019-03-25
CA2637262A1 (en) 2007-08-09
JP6944989B2 (ja) 2021-10-06
AU2012200863B2 (en) 2014-08-28
IL192878A0 (en) 2009-02-11
IL254184A0 (en) 2017-10-31
US20110189163A1 (en) 2011-08-04
JP2012070758A (ja) 2012-04-12
CN105999244A (zh) 2016-10-12
EP4483952A3 (en) 2025-04-02
US20240299508A1 (en) 2024-09-12
JP6230200B2 (ja) 2017-11-15
EP1987141A2 (en) 2008-11-05
US20070224183A1 (en) 2007-09-27
US20110243920A1 (en) 2011-10-06
IL291175B2 (en) 2024-02-01
IL245434A0 (en) 2016-06-30
US20170087229A1 (en) 2017-03-30
US20110158972A1 (en) 2011-06-30
US20230158127A1 (en) 2023-05-25

Similar Documents

Publication Publication Date Title
DK2474321T3 (da) Sammensætninger til behandling af collagenmedierede sygdomme
DK1874781T3 (da) Dihydrothienopyrimidiner til behandling af inflammatoriske sygdomme
DK2478907T3 (da) Sammensætninger til behandling af kræft
PL3354276T3 (pl) Kompozycje do leczenia zapalenia przewodu pokarmowego
DK2504005T3 (da) Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme
DK3456707T3 (da) 4-(p-quinonyl)-2-hydroxybutanamidderivater til behandling af mitokondriesygdomme
DK2056842T3 (da) Modificeret galactosylceramid til behandling af cancerøse sygdomme
DK2137537T3 (da) Sammensætninger og anvendelser til behandling af multipel sklerose
DK2154971T3 (da) Synergistisk farmaceutisk kombination til behandling af cancer
DK2019683T4 (da) Indgivelse af vækstfaktorer til behandling af CNS-lidelser
DK2086944T3 (da) Fremgangsmåde til fremstilling af difluormethylpyrazolylcarboxylater
DK2056807T3 (da) Behandling af inflammatoriske sygdomme
DK1928438T3 (da) Anvendelse af ibudilast til behandling af stofafhængighed
DK2285808T3 (da) Spiroindolderivater til behandling af parasitsygdomme
DK1868579T3 (da) Farmaceutisk sammensætning omfattende en omega-carboxyaryl sunstitueret diphenylurea til behandling af cancer
DK2010184T3 (da) Implatanter til behandlingen af dopamin associerede tilstande
PL2205720T3 (pl) Kompozycja do leczenia stwardnienia rozsianego
DK2216021T3 (da) Farmaceutisk sammensætning til behandling af overaktiv blære
DK1937633T3 (da) Biphenyloxyeddikesyrederivater til behandling af respiratoriske sygdomme
EP2135858A4 (en) COMPOSITION FOR TREATING INFECTIOUS DISEASES
DK2117565T3 (da) Anvendelse af chitosaner til behandlingen af negleinflammatoriske sygdomme
DK2099446T3 (da) Fremgangsmåde til behandling af inflammatorisk tarmsygdom
DK2022504T3 (da) Salve til behandling af hæmorider
FI20095600L (fi) Koostumus ihosairauksien hoitoa varten
EP2210621A4 (en) COMPOSITION FOR TREATING JOINT DISEASE